AEON Biopharma, Inc. (AEON): debt financing — AEON Biopharma secures $15M convertible note from Daewoong and aligns with FDA on Phase 3 migraine trial design

AEON Biopharma, Inc.

Issues up to $15M senior secured convertible notes to Daewoong; first $5M tranche closes within 10 days, second $10M subject to license amendment.
Terminates forward purchase agreements with ACM and Polar; retains ~3.1M shares each, up to $1.5M liquidated damages for registration failures.
FDA confirms primary endpoint (change in mean monthly migraine days over weeks 13-24) for Phase 3 episodic and chronic migraine programs.
Interim analysis of ongoing Phase 2 chronic migraine study now planned; data expected Q2 2024, complete top-line data on track for Q3 2024.
ABP-450 Phase 2 chronic migraine study enrolled 492 patients; will use patented injection paradigm with fewer injections than current treatment.

item 1.01 item 1.02 item 2.03 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

AEON Biopharma, Inc. incurred convertible notes of $15.0 million with Daewoong Pharmaceutical Co., LTD. at 15.79% maturing three years from the funding date.

Instrument: convertible notes
Principal: $15.0 million
Counterparty: Daewoong Pharmaceutical Co., LTD.
Rate: 15.79%
Maturity: three years from the funding date
Event: incurrence

Exact text from the filing

On March 19, 2024, AEON Biopharma, Inc. (“AEON” or the “Company”) and AEON Biopharma Sub, Inc., a subsidiary of the Company (“AEON Sub”), entered into a subscription agreement (the “Subscription Agreement”) with Daewoong Pharmaceutical Co., LTD. (“Daewoong”) relating to the sale and issuance by the Company of senior secured convertible notes (each, a “Convertible Note” and together, the “Convertible Notes”) in the principal amount of up to $15.0 million

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AEON Biopharma, Inc. entered into Subscription Agreement with Daewoong Pharmaceutical Co., LTD. valued at $15.0 million (effective 2024-03-19).

Action: entry
Agreement: equity purchase
Counterparty: Daewoong Pharmaceutical Co., LTD.
Value: $15.0 million
Effective: 2024-03-19

Exact text from the filing

On March 19, 2024, AEON Biopharma, Inc. (“AEON” or the “Company”) and AEON Biopharma Sub, Inc., a subsidiary of the Company (“AEON Sub”), entered into a subscription agreement (the “Subscription Agreement”) with Daewoong Pharmaceutical Co., LTD. (“Daewoong”) relating to the sale and issuance by the Company of senior secured convertible notes (each, a “Convertible Note” and together, the “Convertible Notes”) in the principal amount of up to $15.0 million

View on SEC.gov

299 debt financings filed in the last 30 days. Browse all debt financings →

AEON Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001837607-24-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.